$GILD (Gilead Sciences Inc.)

$GILD {{ '2015-11-30T16:10:13+0000' | timeago}} • SEC

As of Sept. 30, 2015, $GILD's cash, cash equivalents and marketable securities rose by $13.4Bil to $25.1Bil from Dec. 31, 2014. During 9 months ended Sept. 30, 2015, $GILD generated $15.5Bil in cash flows from operations, received $9.9Bil in net proceeds from issuance of its 2015 Notes and repurchased $7Bil of common stock.

$GILD {{ '2017-07-27T18:32:52+0000' | timeago}} • Announcement

$GILD declared a cash dividend of $0.52 per share of common stock for 3Q17, payable on September 28, 2017, to stockholders of record on September 15, 2017.

$GILD {{ '2017-07-26T21:10:46+0000' | timeago}} • Infographic

$GILD Gilead Sciences Earnings AlphaGraphic: Q2 2017 Highlights

$GILD {{ '2017-07-26T20:37:51+0000' | timeago}} • Announcement

$GILD revised its FY17 guidance. The company now expects net product sales to be $24-25.5Bil in FY17. Non-HCV product sales are expected to be $15.5-16Bil while HCV product sales are expected to be $8.5-9.5Bil. Adjusted product gross margin is expected to be 86-88% in FY17.

$GILD {{ '2017-07-26T20:33:53+0000' | timeago}} • Announcement

$GILD's total product sales for 2Q17 were $7Bil compared to $7.7Bil for 2Q16. Product sales were $5Bil in the US, $1.4Bil in Europe and $665MM in other locations during 2Q17. Antiviral product sales were $6.4Bil and Other product sales were $607MM for 2Q17.

$GILD {{ '2017-07-26T20:29:32+0000' | timeago}} • Announcement

$GILD posted a slight decrease in 2Q17 results. Net income was $3.1Bil or $2.33 per share compared to $3.5Bil or $2.58 per share in 2Q16. Adjusted net income was $3.4Bil or $2.56 per share in 2Q17. Total revenues were $7.1Bil compared to $7.8Bil in the prior-year period.

$GILD {{ '2017-07-24T13:41:56+0000' | timeago}} • Announcement

$GILD announced results from two Phase 3 studies evaluating the efficacy and safety of a fixed-dose combination of bictegravir (BIC) and emtricitabine/tenofovir alafenamide (FTC/TAF) for the treatment of HIV-1 infection in treatment-naïve adults. This regimen has been well tolerated with low rates of discontinuations due to adverse events.

$GILD {{ '2017-07-18T20:14:00+0000' | timeago}} • Announcement

$GILD said the US FDA has approved Vosevi tablets, a single-tablet regimen for the re-treatment of chronic hepatitis C virus (HCV) infection in adults previously treated with or without an NS5A inhibitor-containing regimen. The approval is based on data from the Phase 3 POLARIS-1 and POLARIS-4 studies.

$GILD {{ '2017-07-13T13:10:29+0000' | timeago}} • Announcement

$GILD said its Marketing Authorization Application for an investigational, once-daily single tablet regimen containing bictegravir and emtricitabine/tenofovir alafenamide, formulations for treatment of HIV-1 infection in adults, has been fully validated. Currently, they are under evaluation by the European Medicines Agency.

$GILD {{ '2017-06-23T12:05:41+0000' | timeago}} • Announcement

$GILD said the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency(EMA), has adopted a positive opinion on its Marketing Authorization Application (MAA) for Vosevi for the treatment of chronic hepatitis C virus (HCV)-infected patients.

$GILD {{ '2017-06-12T15:03:28+0000' | timeago}} • Announcement

$GILD has submitted a New Drug Application to the FDA for an investigational, once-daily single tablet regimen for the treatment of HIV-1 infection in adults.

$GILD {{ '2017-05-30T14:13:41+0000' | timeago}} • Announcement

$GILD announced that four Phase 3 studies evaluating a fixed-dose combination of bictegravir (50mg) (BIC)  and emtricitabine/tenofovir alafenamide (200/25mg) (FTC/TAF) for the treatment of HIV-1 infection met their primary objectives of non-inferiority.

$GILD {{ '2017-05-05T19:17:07+0000' | timeago}} • Infographic

$GILD Gilead Sciences Earnings AlphaGraphics: Q1 2017 highlights

$GILD {{ '2017-05-02T21:57:30+0000' | timeago}} • Webcast

$GILD stated that the news about futility analysis is a rumor. The company clarified that it does not have an interim analysis planned in Phase III study. The study will be carried out for 48 weeks, $GILD said.

$GILD {{ '2017-05-02T21:45:49+0000' | timeago}} • Webcast

$GILD stated that about 55% of HIV sales is from public and about 45% is from the private in U.S. Of that 55%, 20% or so is from AIDS Drug Assistance Program (ADAP).

$GILD {{ '2017-05-02T21:24:29+0000' | timeago}} • Announcement

$GILD BoD has declared a cash dividend of $0.52 per share of common stock for 2Q17. The dividend is payable on June 29, 2017, to stockholders of record as on June 16, 2017.

$GILD {{ '2017-05-02T20:29:54+0000' | timeago}} • Announcement

$GILD's total product sales for 1Q17 were $6.4Bil compared to $7.7Bil for the same period in 2016. Geographically, sales were $4.5Bil in the US, $1.3Bil in Europe and $661MM in other locations.This compares to prior-year period's sales of $4.4Bil in the US, $1.6Bil in Europe and $1.7Bil in other locations.

$GILD {{ '2017-05-02T20:24:45+0000' | timeago}} • Announcement

$GILD reiterated its FY17 guidance provided on February 7, 2017. Product sales are predicted in the range of $22.5-24.5Bil, while Product Gross Margin is expected between 86% and 88%.

$GILD {{ '2017-05-02T20:18:20+0000' | timeago}} • Announcement

Biotechnology company $GILD posted lower revenue and earnings in 1Q17. Revenue slid 16% to $6.5Bil, hurt by lower product sales, which declined 17% YoY.  Net income was $2.7Bil or $2.05 per share, compared to $3.6Bil or $2.53 per share last year. Excluding special items, $GILD earned $2.23 per share.

$GILD {{ '2017-04-21T12:55:32+0000' | timeago}} • Announcement

$GILD announced results from an open-label, proof-of-concept study evaluating GS-0976, an investigational inhibitor of Acetyl-CoA carboxylase, in patients with nonalcoholic steatohepatitis. The data indicated treatment was associated with statistically significant improvements in liver fat content and noninvasive markers of fibrosis.

$GILD {{ '2017-04-07T17:24:03+0000' | timeago}} • Announcement

$GILD said  the U.S. Food and Drug Administration (FDA) has approved supplemental indications for Harvoni tablets and Sovaldi tablets in pediatric patients 12 years and older with chronic hepatitis C virus (HCV) infection.

Recent Transcripts

GILD (Gilead Sciences Inc.)
Wednesday, July 26 2017 - 8:30pm
AMGN (Amgen Inc)
Tuesday, July 25 2017 - 9:00pm
BIIB (Biogen Inc.)
Tuesday, July 25 2017 - 12:00pm
ONVO (Organovo Holdings, Inc.)
Wednesday, June 7 2017 - 9:00pm
MDT (Medtronic plc)
Thursday, May 25 2017 - 12:00pm
VRML (Vermillion, Inc.)
Thursday, May 11 2017 - 12:30pm
SGMO (Sangamo Biosciences Inc.)
Wednesday, May 10 2017 - 9:00pm
ATRS (Antares Pharma Inc.)
Tuesday, May 9 2017 - 12:30pm
AGN (Allergan plc)
Tuesday, May 9 2017 - 12:30pm
REGN (Regeneron Pharmaceuticals, Inc.)
Thursday, May 4 2017 - 12:30pm
INSM (Insmed Incorporated)
Wednesday, May 3 2017 - 12:30pm
AMRN (Amarin Corporation plc)
Wednesday, May 3 2017 - 12:00pm
KTWO (K2M Group Holdings, Inc.)
Tuesday, May 2 2017 - 9:00pm
GILD (Gilead Sciences Inc.)
Tuesday, May 2 2017 - 8:30pm
CYH (Community Health Systems, Inc.)
Tuesday, May 2 2017 - 4:00pm
TECH (Bio-Techne Corp.)
Tuesday, May 2 2017 - 1:00pm
SGEN (Seattle Genetics, Inc.)
Thursday, April 27 2017 - 8:30pm
BMY (Bristol-Myers Squibb Company)
Thursday, April 27 2017 - 2:30pm
ALXN (Alexion Pharmaceuticals, Inc.)
Thursday, April 27 2017 - 2:00pm
CELG (Celgene Corporation)
Thursday, April 27 2017 - 1:00pm

AlphaGraphics you may like